Clinical evaluation of dicumarinyl derivatives with a metabolic study of the radioactively labeled anticoagulants in animals.

The common use of dicumarinyl derivatives for the treatment of thromboembolic diseases justifies further clinical evaluation of dicumarol and 4,4'-dihydroxydicumarinyl ethyl acetate [Pelentan, Tromexan, 3,3'-carboxymethylenebis (4-hydroxycoumarin) ethyl ester.] The need for a more thorough understanding of the pharmacodynamic action of dicumarinyl anticoagulants has prompted a study of their gross metabolism in animals, using C'4-labeled materials.